MedPath

Comparison of duration of analgesia Between Ropivacaine Heavy With Fentanyl and Ropivacaine Heavy with Dexmedetomidine in spinal anaesthesia for below umbilical surgeries

Not yet recruiting
Conditions
Medical and Surgical,
Registration Number
CTRI/2022/10/046403
Lead Sponsor
Vijayanagar institute of medical sciences
Brief Summary

Spinal anaesthesia is widely used technique for infra umbilical surgeries providing fast onset and effective sensory and motor blockade and prolonged postoperative analgesia.spinal hyperbaric Ropivacaine may produce more reliable and predictable anaesthesia than plain Ropivacaine. Among the various adjuvants added to intrathecal spinal anaesthesia Dexmedetomidine and Fentanyl are commonly used. Recently hyperbaric Ropivacaine is being introduced into the clinical practice and there is a dearth in literature regarding use of hyperbaric Ropivacaine for subarachnoid block. Hence this study is designed to investigate and compare the effects of Hyperbaric Ropivacaine with additives such as Fentanyl and Dexmedetomidine on spinal anaesthesia.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
62
Inclusion Criteria

Patients undergoing lower abdominal surgeries.

Exclusion Criteria

Patient refusal for spinal anaesthesia History of allergy to drugs Any contraindication for spinal anaesthesia Deformity of lumbosacral spine.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Less postoperative analgesia requiredFrom intrathecal administration of drug till two segment regression
Secondary Outcome Measures
NameTimeMethod
Onset of sensory blockadeOnset of motor blockade

Trial Locations

Locations (1)

Vijayanagar institute of medical sciences

🇮🇳

Bellary, KARNATAKA, India

Vijayanagar institute of medical sciences
🇮🇳Bellary, KARNATAKA, India
SUPRITA SURESH NAIK
Principal investigator
8105747799
supritanaik08@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.